Abstracts in vitro suggèrent fortement l'implication de SYK dans cette phosphorylation.
Results -We evaluated in 449 patients with non-ST elevation ACS after the administration of a loading dose of 600 mg clopidogrel, the impact of CYP2C19*17 on platelet response to clopidogrel assessed by vasodilator stimulated phosphoprotein phosphorylation index (PRI VASP). No signiÀ cant deviations from Hardy-Weinberg equilibrium were observed for this genetic variant. The observed frequency of the CYP2C19*17 allele was 20 %. The CYP2C19*17 allele was signiÀ cantly associated with VASP, both in recessive (p =0.02) and codominant (p =0.0073) models. The CYP2C19*17 allele carriers (extensive metabolizers) exhibited the lowest PRI VASP (mean ± SD = 49.7±23.7 vs 55.9±22.8), testifying a better platelet response to clopidogrel. The interaction between the CYP2C19*2 (decrease in platelet response to clopidogrel) an the CYP2C19*17 allele (increase in platelet response to clopidogrel) was not signiÀ cant.
Conclusion -The present data suggest that the CYPC19*17 allele inÁ uences platelet response to clopidogrel in patients with NSTE ACS, independently from the CYPC19*2 allele. Platelet tests did not correlate with glycemic control and did not change after glycemic optimization. Type 2 diabetics had higher ADP-Ag and PRI VASP than type 1 (49±19 vs 33±19 %, p = 0.008 ; 62±16 vs 48±27 %, p = 0.02, respectively). On adjustment for studied variables ADP-Ag but not PRI VASP remained statistically associated with the type of diabetes (p = 0.007 ; p=0.11 respectively). Also À brinogen was an independent predictor of ADP-Ag and clopidogrel non responders had elevated plasma À brinogen, compared with responders: 8.2 ± 0.5 versus 3.8 ± 0.1 g/L (p<10 -4 ). A threshold of 3.57 g/L led to a negative predictive value of 94.7 %.
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Conclusion -Platelet response to clopidogrel, mainly ADP-Ag was not related to glycemic control but to the type of diabetes. Moreover À brinogen strongly predicted ADP-Ag in diabetics.
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PCSK9 DEFICIENT MICE ARE NOT PROTECTED AGAINST HYPERCHOLESTEROLEMIA WHEN FED A HIGH FAT DIET
C. LE MAY 1 , B. CARIOU 1 , P. COSTET 1 1 Inserm U915, Nantes, France Introduction -Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low density lipoprotein receptor (LDLr) and its deÀ ciency confers a high protection against cardiovascular diseases. We previously reported that PCSK9 expression is regulated by nutritional status and insulinemia.
Objectives -Here, we investigated the metabolic adaptation of PCSK9 deÀ cient mice (PCSK9-/-) in response to a high fat diet (HFD).
Methods & Results -PCSK9-/-and PCSK9+/+ males were given a 60 % fat diet for 10 weeks. Before treatment, both genotypes responded similarly to oral glucose tolerance (OGTT) and insulin tolerance test (ITT). The À rst week following HFD feeding, we noticed an initial rise in glycemia for both genotypes (32 and 37.8 %), reÁ ecting diet-induced insulin resistance. Despite comparable OGTT and ITT, PCSK9-/-mice presented a slight reduction of blood glucose compared to PCSK9+/+ littermates during the all period of HFD feeding. By contrast, PCSK9 deÀ ciency did not alter body weight, plasma triglyceride or free fatty acids levels in response to HFD. On regular diet, PCSK9-/-mice have signiÀ cant reduction of circulating cholesterol compared to PCSK9+/+ mice (0.721±0.05 g/l vs 1.06±0.04 P=0.0002). Surprisingly, after one week of diet, this phenotype was lost and cholesterol levels were not signiÀ cantly different between PCSK9-/-and PCSK9+/+ mice (respectively: 1.327±0.07 g/l vs 1.501±0.05 P=0.065).
Introduction -Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low density lipoprotein receptor (LDLR) and its deÀ ciency confers a high level of protection against cardiovascular disease. PCSK9 is well expressed in the liver and the intestine but its precise localization and its role in the digestive tract remain unknown.
Objectives -The aim of this study is to determine PCSK9 distribution and localization in the intestine and examine in mice whether it acts upon postprandial lipemia.
Methods & Results -In mice, we show that PCSK9 mRNA is highly expressed all along the small intestine and colon. Confocal microscopy on human intestines showed that PCSK9 is localized mainly in the enterocyte. Similar to hepatocytes, PCSK9 was induced by statins in polarized Caco-2 cells. Upon olive oil gavage, and in spite of similar fasting triglyceridemia, PCSK9-/-mice have a dramatically decreased postprandial triglyceridemia compared with their wild type littermates (WT) (0.075 g/L/h vs 0.2 g/L/h, p<0.01). Lymph analysis revealed that intestinal TG output is not quantitatively modiÀ ed by PCSK9 deletion. However, PCSK9-/mice present a signiÀ cant reduction of lymphatic apoB secretion compared to PCSK9+/+ mice. Modulating PCSK9 expression in polarized Caco-2 cells conÀ rmed the relationship between PCSK9 and apoB secretion ; PCSK9-/-mice consistently secrete larger TGrich lipoprotein than wild-type littermates. Finally, kinetic studies showed that PCSK9 deÀ cient mice have an increased ability to clear chylomicrons compared to wild-type littermates.
Conclusions -Altogether, these data suggest that PCSK9 deÀ ciency might protect against cardiovascular disease not only by affecting the LDLC but also by reducing postprandial triglyceridemia, an important risk factor.
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CARACTÉRISATION DES CELLULES ENDOTHÉLIALES DU TISSU ADIPEUX HUMAIN SOUS-CUTANÉ
A. VILLARET 1 , L. DANOUX 1 , C. JEANMAIRE 1 , G. PAULY 1 , M. LAFONTAN 2 , A. BOULOUMIE 2 1 Laboratoires Serobiologiques Cognis, Nancy, France 2 Inserm U858 I2MR, Toulouse, France Le tissu adipeux est un organe jouant un rôle majeur dans le maintien de l'homéostasie métabolique. De plus, la masse grasse a acquis le statut d'organe endocrine. EnÀ n, récemment, la présence de cellules du système immunitaire a été mise en évidence dans le tissu adipeux et suggérée comme étant responsable du développement de l'inÁ ammation chronique de bas niveau associée à l'obésité. Ces échanges de métabolites, d'hormones et de cellules entre compartiment adipeux et sanguin démontrent le rôle prépondérant de l'endothélium dans la masse grasse. Or, chez l'homme aucune étude n'a décrit l'endothélium du tissu adipeux. Cette étude a été menée aÀ n de caractériser le système capillaire du tissu adipeux humain sous-cutané abdominal et d'évaluer l'inÁ uence du degré d'adiposité des patients sur l'état d'activation des cellules endothéliales du tissu adipeux humain.
Nous avons déterminé, par observation in situ en immunoÁ uorescence que le tissu adipeux humain possédait un réseau capillaire très développé caractérisé par la double expression des marqueurs de surface CD31 et CD34. L'analyse en cytométrie en Á ux du nombre de cellules CD31+/CD34+ du tissu adipeux de patientes normopondérées (indice de masse corporelle (IMC) compris entre 20 et 25) et obèses (IMC supérieur à 30) a montré que le nombre de cellules CD31+/CD34+ est maintenu constant, démontrant que la croissance excessive du tissu adipeux s'accompagne d'une extension de son réseau capillaire. La caractérisation par PCR quantitative en temps réel de transcrits exprimés dans les cellules endothéliales capillaires CD31+/CD34+ du tissu adipeux humain isolées par une technique d'immunosélection/déplétion a mis en évidence un état d'activation inÁ ammatoire et angiogénique de ces cellules chez les sujets obèses. De plus, nous avons développé une technique de culture primaire de ces cellules permettant le maintien de l'expression des marqueurs endothéliaux.
En conclusion, cette étude a permis de mettre au point des techniques d'immunohistochimie en Á uorescence des réseaux capillaires du tissu adipeux humain et de culture primaire des cellules endothéliales. De plus, nos résultats montrent que le développement de la masse grasse chez l'homme module le phénotype des cellules endothéliales (activation inÁ ammatoire et angiogénique).
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EFFETS SUR LA FONCTION PLAQUETTAIRE ET LE STATUT REDOX D'UNE SUPPLEMENTATION EN ACIDE DOCOSAHEXAENOÏQUE CHEZ DES HOMMES SAINS
